Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations

Mult Scler Relat Disord. 2020 Aug:43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alemtuzumab / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Chile / epidemiology
  • Coronavirus Infections / epidemiology
  • Decision Making
  • Female
  • Fingolimod Hydrochloride / therapeutic use
  • Glatiramer Acetate / therapeutic use
  • Guideline Adherence
  • Guidelines as Topic
  • Health Behavior*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferons / therapeutic use
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis, Chronic Progressive / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Natalizumab / therapeutic use
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Quarantine*
  • SARS-CoV-2
  • World Health Organization
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Natalizumab
  • Alemtuzumab
  • Glatiramer Acetate
  • Interferons
  • ocrelizumab
  • Fingolimod Hydrochloride